Literature DB >> 12455806

Prophylactic antibiotics in cirrhotics with upper gastrointestinal hemorrhage: a prospective, controlled trial.

Ying-Tsun Lin1, Gin-Ho Lo, Kwok-Hung Lai, Tai-An Chen, Whey-Jen Lin.   

Abstract

BACKGROUND: Infections are a frequent complication in cirrhotics, and gastrointestinal bleeding may increase the infection rate. Nonabsorbable antibiotics or quinolone have been employed to decrease the incidence of infection. Since most of these studies were performed in western countries, it is still unclear whether this holds true in our Taiwan cirrhotic patients. Thus we conducted this study using a different formula of antibiotics to evaluate the efficacy of reducing infection rates in cirrhotics with upper gastrointestinal bleeding.
METHODS: From July 1999 to August 2000, all cirrhotic in-patients presenting with upper gastrointestinal bleeding but without infection were enrolled. The patients should not have received antibiotics within 2 weeks before admission and should have expected life expectance more than 7 days. Eligible patients who had received endoscopy within 12 hours of hospitalization were randomly allocated into 2 groups. Group A received intravenous cefazolin 1 gm every 8 hours started before endoscopy. After 3 days of prophylactic parenteral antibiotics, antibiotics were shifted to oral cephalexin of 500 mg every 6 hours for 4 days. Group B served as control subjects. All patients received chest X-ray, blood and urine cultures, and ascites culture and sputum culture if ascites and sputum were found. Patients were excluded when initial blood, urine or ascites culture was positive for bacterial growth.
RESULTS: Ninety-seven patients were included. Group A was comprised of 47 patients and Group B comprised of 50 patients. There was no significant difference in age, sex, Child-Pugh's score or initial hemoglobin between the 2 groups. Proved infection developed in 6 patients of Group B. By contrast, no proved infection was found in Group A. Three organisms belonged to gram-negative bacilli and 3 organisms were gram-positive cocci. The incidence of proved infection during hospitalization was 0% in Group A and 12.0% in Group B (p = 0.027). If possible infection cases (patient's body temperature more than 38 degrees C for more than 2 days) were included, the infection rate was 6.4% in Group A and 26% in Group B (p = 0.013). Infection-related mortality occurred in 2 patients in Group B, but none in Group A.
CONCLUSIONS: Our prophylactic antibiotic treatment proved safe and effective in reducing the infection rate in cirrhotics with upper gastrointestinal bleeding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12455806

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi (Taipei)        ISSN: 0578-1337


  4 in total

1.  A retrospective study of bacterial infections in cirrhosis.

Authors:  Carmen Monica Preda; Ruxandra Ghita; Camelia Ghita; Cezarina Mindru; Livia Vlaicu; Adriana Andrei; Sorin Andrei; Mircea Diculescu
Journal:  Maedica (Bucur)       Date:  2011-07

Review 2.  Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding.

Authors:  Norberto C Chavez-Tapia; Tonatiuh Barrientos-Gutierrez; Felix I Tellez-Avila; Karla Soares-Weiser; Misael Uribe
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

3.  Bacterial infections in acute variceal hemorrhage despite antibiotics-a multicenter study of predictors and clinical impact.

Authors:  Stephen Lee; Lynora Saxinger; Mang Ma; Verónica Prado; Joaquin Fernández; Deepali Kumar; Juan Gonzalez-Abraldes; Adam Keough; Ravin Bastiampillai; Michelle Carbonneau; Javier Fernandez; Puneeta Tandon
Journal:  United European Gastroenterol J       Date:  2017-04-04       Impact factor: 4.623

4.  The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.

Authors:  Cheng-Kun Wu; Jing-Houng Wang; Chen-Hsiang Lee; Keng-Liang Wu; Wei-Chen Tai; Sheng-Nan Lu; Tsung-Hui Hu; Seng-Kee Chuah
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.